Altered brain glucose metabolism in transgenic-PFKL mice with elevated L-phosphofructokinase: In vivo NMR studies

Brain Research

Volumn 810, Issue 1-2, 1998, Pages 138-145

  Peled Kamar, Mira ^a   Degani, Hadassa ^a   Bendel, Peter ^a   Margalit, Ra'Anan ^a   Groner, Yoram ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Gene dosage; Glucose metabolism; In vivo NMR; Phosphofructokinase; Transgenic mouse

Indexed keywords

6 PHOSPHOFRUCTOKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN METABOLISM; COGNITIVE DEFECT; CONTROLLED STUDY; DOWN SYNDROME; GLUCOSE METABOLISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; BLOOD GLUCOSE; BRAIN CHEMISTRY; GLUCOSE; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, TRANSGENIC; PHOSPHOFRUCTOKINASE-1;

EID: 0032501224     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00899-3     Document Type: Article

References (54)

1. Anneren K.G., Korenberg J.R., Epstein C.J. Phosphofructokinase activity in fibroblasts aneuploid for chromosome 21. Hum. Genet. 76:1987;63-65.
2. 13C NMR for the assessment of human brain glucose metabolism in vivo Biochemistry. 30:1991;6362-6366.
3. C.E. Benda (Ed.), Down's syndrome: Mongolism and its Management, Grune and Stratton, New York, 1969.
4. Bergman R.N., Steil G.M., Bradley D.C., R.M W. Modeling of insulin action in vivo. Annu. Rev. Physiol. 54:1992;861-883.
5. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
6. G.F.J. Cahill, O.E. Owen, Some observations on carbohydrate metabolism in man, in: F. Dickens, P.J. Randle, W.J. Whelan (Eds.), Carbohydrate Metabolism and its Disorders, Vol. 1, Academic Press, 1968, pp. 497-522.
7. Cooper D.N., Hall C. Down's syndrome and the molecular biology of chromosome 21. Prog. Neurobiol. 30:1988;507-530.
8. Cox D.R., Kawashima H., Vora S., Epstein C. Regional mapping of SOD, PRGS and PFKL on chromosome 21. Cytogenet. Cell. Genet. 37:1984;441-442.
9. Crane P.D., Pardridge W.M., Braun L.D., Nyerges A.M., Oldendorf W.H. The interaction of transport and metabolism on brain glucose utilization: a re-evaluation of the lumped constant. Neurochemistry. 36:1981;1601-1604.
10. 18F ] 2-deoxy-D-glucose: healthy aging, Alzheimer's disease and down syndrome J. Neur. Psych. Biol. Psychiatry. 10:1986;309-321.
11. Dunaway G.A. A review of animal phosphofructokinase isozymes with an emphasis on their physiological role. Mol. Cell. Biochem. 52:1983;75-91.
12. Dunaway G.A., Kasten T.P. Physiological implications of the alteration of 6-phosphofructo-1-kinase isozyme pools during brain development and aging. Brain Res. 456:1988;310-316.
13. Dunaway G.A., Kasten T.P. Physiological relevance of the changing subunit composition and regulatory properties of the 6-phospho-1-fructokinase isozyme pools during heart and muscle development. Mol. Cell. Biochem. 87:1989;71-77.
14. Dunaway G.A., Kasten T.P., Sebo T., Trapp R. Analysis of the phosphofructokinase subunits and isoenzymes in human tissues. Biochem. J. 251:1988;677-683.
15. Elson A., Bernstein Y., Degani H., Levanon D., Ben-Hur H., Groner Y. Gene dosage and Down's syndrome: metabolic and enzymatic changes in PC12 cells overexpressing transfected human liver-type phosphofructokinase. Somatic Cell and Mol. Genet. 18:1992;143-161.
16. Elson A., Weiss Y., Groner Y. Protein kinase C (PKC) level is increased in PC12 cells overexpressing transfected liver-type phosphofructokinase. Biol. Cell. 81:1994;23-29.
17. Elson A., Levanon D., Weiss Y., Groner Y. Overexpression of liver-type phosphofructokinase (PFKL) in transgenic-PFKL mice: implication for gene dosage in trisomy 21. Biochem. J. 299:1994;409-415.
18. C.J. Epstein, The consequences of chromosome imbalance - Principles, Mechanisms, Models, Cambridge University Press, Cambridge, 1986.
19. C.J. Epstein, in: C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.), The Metabolic Basis of Inherited Disease, McGraw-Hill, New York, 1989, pp. 291-326.
20. V. Estmann (Ed.), Regulatory Mechanisms of Carbohydrate Metabolism, Pergamon, 1978.
21. U. Francke, Gene dosage studies in Down's syndrome: a review, in: F.F. de la Cruz, P.S. Gerald (Eds.), Trisomy 21 (Down's syndrome) Research Perspective, University Park Press, Baltimore, 1981, pp. 275-280.
22. Y. Groner, A. Elson, Down's syndrome molecular genetics, in: R. Dulbecco (Ed.), Encyclopedia of Human Biology, Vol. 3, Academic Press, New York, 1991, pp. 175-189.
23. 13C ] glucose J. Neurochem. 63:1994;1377-1383.
24. 13C NMR spectroscopy Proc. Natl. Acad. Sci. USA. 89:1992;1109-1112.
25. Hawkins R.A., Mans A.W., Davis D.W., Hibbard L.S., Lu D.M. Glucose availability to individual cerebral structure is correlated to glucose metabolism. J. Neurochem. 40:1983;1013-1018.
26. Jagust W.J., Eberling J.L., Richardson B.C., Reed B.R., Baker M.G., Nordahl T.E., Budinger T.F. The cortical topography of temporal lobe hypometabolism in early Alzheimer's disease. Brain Res. 629:1993;189-198.
27. Kedziora J., Hubner H., Kanski M., Jeske J., Leyko W. Efficiency of the glycolytic pathway in erythrocytes of children with Down's syndrome. Pediatr. Res. 61:1972;10-17.
28. Knobler H., Weiss Y., Peler-Kamar M., Groner Y. Impaired glucose-induced insulin response in transgenic mice overexpressing the L-phosphofructokinase. Diabetes. 46:1997;1414-1418.
29. J.R. Korenberg, Molecular mapping of the Down syndrome phenotype, in: D. Patterson, C.J. Epstein (Eds.), Molecular Genetic of Chromosome 21 and Downs Syndrome, 1990, pp. 105-115.
30. Korenberg J.R., X.-N C., Schipper R., Sun Z., Gronsky R., Gerwehr S., Carpenter N., Daumer C., Dignan P., Disteche C., Graham J.M., Hugdins L., McGillivary B., Miyazaki K., Ogasawara N., Park J.P., Pagon R., Pueschel S., Sack G., Say B., Schuffenhauer S., Soukup S., Yamanaka T. Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc. Natl. Acad. Sci. USA. 91:1994;4997-5001.
31. A. Lapidot, A. Gopher, S.H. Korman, H. Mandel, Ninth Annual Scientific Meeting of the Society of Magnetic Resonance in Medicine, New York, 1990, abstract.
32. Levanon D., Brandeis M., Bernstein Y., Groner Y. Common promoter features in human and mouse liver-type phosphofructokinase gene. Biochem. Mol. Biol. Int. 35:1995;929-936.
33. I.T. Lott, E.E. McCoy (Eds.), Down Syndrome - Advances in Medical Care, Wiley-Liss Publications, 1992.
34. Magnani M., Stocchi V., Novelli G., Dacha M., Forniani G. Red blood cell glucose metabolism in Down's syndrome. Clin. Physiol. Biochem. 5:1987;9-14.
35. Meienhofer M.C., Lagrange J.C., Coureau D., Lenoir G., Dreyfus J.C., Kahn A. Phosphofructokinase in human blood cells. Blood. 54:1979;389-400.
36. Pardridge W.M. Brain metabolism: a perspective from the blood-brain barrier. Physiol. Rev. 63:1983;1481-1535.
37. Parra J., Pette D. Effects of low-frequency stimulation on soluble and structure-bound activities of hexokinase and phosphofructokinase in rat fast-twitch muscle. Biochem. Biophys. Acta. 1252:1995;154-160.
38. Prichard J.W. NMR spectroscopy of brain metabolism in vivo. Ann. Rev. Neurosci. 9:1986;61-85.
39. Sadava D., Frykman P., Harris E., Majerus D., Mustard B., Bernard B. Development of enzymes of glycolysis and gluconeogenesis in human fetal liver. Biol. Neonate. 62:1992;89-95.
40. Schapiro M.B., Ball M.J., Grady C.L., Haxby J.V., J.A K., S.I P. Dementia in Down's syndrome: cerebral glucose utilization. Neurology. 38:1988;938-942.
41. Schapiro M.B., Haxby J.V., Grady C.L. Nature of mental retardation and dementia in Down syndrome: study with PET, CT, and neuropsychology. Neurobiology and Aging. 13:1992;723-734.
42. Schwartz M., Duara R., Haxby J., Grady C., White B.J., Kessler R.M., Kay A.D., Cutler N.R., Papoport S.I. Down's syndrome in adults: brain metabolism. Science. 221:1983;781-783.
43. L. Stryer (Ed.), Biochemistry, Freeman and Co., New York, 1988.
44. Stewart G.D., Keuren M.L.V., Galt J., Kurachi S., Buraczynska M.J. Molecular structure of human chromosome 21. Annu. Rev. Genet. 23:1989;409-423.
45. R.L. Summitt, Chromosome 21: specific segments that cause the phenotype of Down syndrome, in: F.F. De La Cruz, P.S. Gerald (Eds.), Trisomy 21 (Down syndrome) Research and Perspective, University Park Press, Baltimore, 1981, pp. 225-235.
46. M. Tolksdorf, H.R. Wiedemann, Clinical aspects of Down's syndrome from infancy to adult life, in: A.R. Burgio, M. Fraccaro, L. Tiepolo, U. Wolf (Eds.), Trisomy 21, an International Symposium, Springer Verlag, Berlin, 1981, pp. 3-32.
47. A.G. Ugazio, Down's syndrome: problems of immunodeficiency, in: G.R. Burgio, M. Fraccaro, L. Tiepollo, U. Wolf (Eds.), Trisomy 21, Springer-Verlag, Berlin/Heidelberg, 1981.
48. Uyeda K. Phosphofructokinase. Adv. Enzymol. 48:1979;193-244.
49. Van Keuren M., Drabkin H., Hart I., Harker D., Patterson D., Vora S. Regional assignment of human liver-type 6-phosphofructokinase to chromosome 21q22.3 by using somatic cell hybrids and a monoclonal anti-L antibody. Hum. Genet. 74:1986;34-40.
50. S. Vora, Isozymes of phosphofructokinase, Current Topics in Biological and Medical Research, Vol. 6, Alan R. Liss, New York, 1982, pp. 119-167.
51. Vora S., C S., S D., S P. Isozymes of human phosphofructokinase: identification and subunit structural characterization of a new system. Biochemistry. 77:1980;62-66.
52. Vora S., Francke U. Assignment of the human gene for liver-type 6-phosphofructokinase isozyme (PFKL) to chromosome 21 by using somatic cell hybrids and monoclonal anti-L antibody. Proc. Natl. Acad. Sci. USA. 78:1981;3738-3742.
53. Vora S., Halper J.P., Knowles D.M. Alterations in the activity and isozymic profile of human phosphofructokinase during malignant transformation in vivo and in vitro: transformation- and progression-linked discriminants of malignancy. Cancer Res. 45:1985;2993-3001.
54. Shulman R.G., Rothman D.L., Blamire A.M. NMR studies of human brain function. TIBS. 19:1994;522-526.